CINECA IRIS Institutional Research Information System

ELISEI, ROSSELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 34.033
EU - Europa 16.610
AS - Asia 16.334
SA - Sud America 2.881
AF - Africa 859
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 18
Totale 70.767
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.124
SG - Singapore 5.019
CN - Cina 4.809
IT - Italia 4.518
DE - Germania 3.749
HK - Hong Kong 3.117
SE - Svezia 2.870
BR - Brasile 2.420
GB - Regno Unito 1.153
BG - Bulgaria 1.146
VN - Vietnam 901
TR - Turchia 723
CA - Canada 690
RU - Federazione Russa 639
AT - Austria 534
FI - Finlandia 508
UA - Ucraina 409
IN - India 403
CI - Costa d'Avorio 390
KR - Corea 368
FR - Francia 264
JP - Giappone 194
SN - Senegal 189
AR - Argentina 164
BD - Bangladesh 147
NL - Olanda 141
CH - Svizzera 139
MX - Messico 110
IQ - Iraq 102
PL - Polonia 100
BE - Belgio 91
ZA - Sudafrica 77
EC - Ecuador 76
MA - Marocco 73
ID - Indonesia 71
PK - Pakistan 68
ES - Italia 66
SA - Arabia Saudita 63
CO - Colombia 50
EE - Estonia 50
VE - Venezuela 47
CZ - Repubblica Ceca 45
UZ - Uzbekistan 45
IR - Iran 38
LT - Lituania 33
GR - Grecia 31
CL - Cile 30
UY - Uruguay 29
PY - Paraguay 27
AU - Australia 26
PH - Filippine 25
AZ - Azerbaigian 24
IE - Irlanda 24
KE - Kenya 24
JO - Giordania 22
IL - Israele 21
MY - Malesia 21
NP - Nepal 21
PE - Perù 21
AE - Emirati Arabi Uniti 20
TW - Taiwan 19
TN - Tunisia 18
EG - Egitto 17
JM - Giamaica 16
PA - Panama 16
RO - Romania 16
OM - Oman 15
RS - Serbia 15
HU - Ungheria 14
NG - Nigeria 14
DZ - Algeria 13
EU - Europa 13
BO - Bolivia 12
CR - Costa Rica 12
KG - Kirghizistan 10
BJ - Benin 9
DO - Repubblica Dominicana 9
HN - Honduras 9
KZ - Kazakistan 9
PT - Portogallo 9
SK - Slovacchia (Repubblica Slovacca) 9
TT - Trinidad e Tobago 8
BH - Bahrain 7
BY - Bielorussia 7
LB - Libano 7
AL - Albania 6
CY - Cipro 6
DK - Danimarca 6
GA - Gabon 6
PS - Palestinian Territory 6
BZ - Belize 5
GE - Georgia 5
GT - Guatemala 5
MG - Madagascar 5
NZ - Nuova Zelanda 5
SV - El Salvador 5
SY - Repubblica araba siriana 5
GY - Guiana 4
LK - Sri Lanka 4
PR - Porto Rico 4
Totale 70.679
Salva come PNG Salva come JPEG
Città #
Ashburn 3.800
Hong Kong 3.077
Woodbridge 2.865
Dallas 2.830
Fairfield 2.810
Singapore 2.715
Chandler 2.118
Ann Arbor 1.965
Houston 1.898
Santa Clara 1.764
Seattle 1.226
Sofia 1.141
Shanghai 1.127
Milan 1.038
Wilmington 1.037
Beijing 1.010
Cambridge 966
New York 901
Boardman 582
Los Angeles 553
Ottawa 521
Princeton 520
Vienna 478
Hefei 444
Lawrence 443
Jacksonville 436
Munich 395
Abidjan 390
Medford 366
Izmir 352
Seoul 344
Serra 333
London 293
Des Moines 278
Nanjing 267
Florence 244
Pisa 244
Istanbul 231
Frankfurt am Main 229
Rome 227
São Paulo 213
Redondo Beach 195
Dearborn 190
Dakar 189
Buffalo 187
Dong Ket 187
Ho Chi Minh City 177
San Diego 167
Tokyo 152
Boulder 133
Bern 120
Bremen 118
Hanoi 112
Düsseldorf 109
Turku 108
Redwood City 107
Nanchang 100
Ogden 90
Chicago 87
Helsinki 87
Brussels 86
Fuzhou 86
Columbus 84
Kunming 75
Rio de Janeiro 75
Washington 75
Jüchen 74
The Dalles 71
Belo Horizonte 69
Changsha 69
Tianjin 69
Council Bluffs 63
Nuremberg 62
Phoenix 59
Lancaster 57
Shenyang 57
Denver 56
Warsaw 56
Naples 55
Kocaeli 54
Montreal 54
Brooklyn 53
Hebei 53
Guangzhou 52
Nürnberg 52
Orem 51
Quanzhou 51
Jiaxing 50
Redmond 49
Atlanta 48
Norwalk 48
Toronto 47
Baghdad 46
Zhengzhou 46
Johannesburg 44
Brasília 43
San Francisco 42
Tashkent 41
Lucca 40
San Jose 40
Totale 47.588
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.089
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 323
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 308
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 280
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 270
null 259
T cell responses to orbital antigens in thyroid-associated ophthalmopathy. 244
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 242
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 241
Advances in the follow-up of differentiated or medullary thyroid cancer. 237
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 236
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 235
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 234
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10 years follow up study 233
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 231
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 230
Circulating neuron-specific enolase in medullary thyroid cancer. 225
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 224
Identification of two distinct molecular subtypes by digital RNA counting of "non-invasive follicular tumour with papillary-like nuclear features (NIFTP)" 224
Studies with recombinant autoepitopes of thyroid peroxidase: evidence suggesting an epitope shared between the thyroid and the gastric parietal cell. 223
Thyroid carcinoma in thyrotoxic patients treated by surgery. 222
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 221
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 221
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 220
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 219
LOW PREVALENCE OF THE SOMATIC M918T RET MUTATION IN MICRO-MEDULLARY THYROID CANCER. 219
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 216
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 215
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 214
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 213
Targeted Therapy in Thyroid Cancer: State of the Art 210
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 209
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 208
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 207
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study 206
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 206
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 206
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 205
Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer 204
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 203
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 200
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 200
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 200
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 200
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 199
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 198
Thyroid cancer in children and adolescents. 197
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium 196
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 196
RET point mutations in Thyroid Carcinoma 196
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 196
Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. 195
Multiple Endocrine Neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 195
Advances in the follow-up of differentiated or medullary thyroid cancer 195
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 194
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade 194
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 192
Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40. 191
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 190
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 189
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 188
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 188
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 188
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 187
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 187
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 186
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 186
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 185
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 184
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 184
Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology 183
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 183
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 182
Inherited variants in genes somatically mutated in thyroid cancer 182
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 182
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 181
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 180
Muscle autoantigens in thyroid associated ophthalmopathy: the limits of molecular genetics. 179
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 179
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 179
Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. 178
Routine serum calcitonin measurement in the evaluation of thyroid nodules 178
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 178
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 178
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 177
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 176
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 176
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 176
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer 174
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 174
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 173
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 173
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 172
Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters 172
Il carcinoma tiroideo: nuove prospettive terapeutiche. 172
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 172
Motesanib diphosphate in progressive differentiated thyroid cancer 171
Post-surgical follow-up of differentiated thyroid cancer. 169
Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes 169
Genome-wide association study on differentiated thyroid cancer. 169
Totale 21.095
Salva come PNG Salva come JPEG
Categoria #
all - tutte 203.591
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 203.591
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.299 0 0 0 0 0 247 277 320 338 316 241 560
2021/20225.311 124 233 126 379 1.096 695 176 241 284 218 338 1.401
2022/20237.672 969 1.121 610 609 765 907 137 613 1.321 73 455 92
2023/20245.333 584 553 635 381 711 924 287 172 141 115 261 569
2024/202516.761 170 657 232 984 1.588 1.502 1.324 922 1.783 2.169 1.848 3.582
2025/202612.452 1.483 2.986 2.551 2.091 1.953 1.388 0 0 0 0 0 0
Totale 71.802